Introduction {#s1}
============

In *Homo sapiens *the skin of the underarm (axilla) provides a unique niche for bacteria. Through the secretions of various glands, that open onto the skin or into hair follicles, this environment is nutrient-rich and hosts a unique microbial community ([@bib77]). Esterified fatty acids and other lipids are secreted by the sebaceous gland, while the eccrine glands produce a dilute salt solution with lactate and other organic solutes being secreted ([@bib10]). A third exocrine gland, the apocrine, which is more specialized and found only in the axilla, areolae, genitalia and external auditory meatus (ear canal) ([@bib15]), starts secreting an odourless lipid-rich viscous secretion with the onset of puberty ([Figure 1A](#fig1){ref-type="fig"}). The lipid rich secretion is not involved in thermoregulation like the eccrine gland and in mammals has a likely role in scent generation ([@bib15]).

![Biochemical route of axillary malodour precursor peptide S-Cys-Gly-3M3SH.\
(**A**) Schematic representation of the axilla. The surface of the skin is composed of the axillary microbiome, typically dominated by either *Corynebacterium* or Staphylococci. Axillary apocrine glands are subcutaneously located in the hypodermis. Apocrine glands secrete a variety of odourless precursors that are bio-transformed into odorous volatiles by the axillary microbiome. Sulfanylalkanols (e.g. 3-methyl-3-sulfanylhexan-1-ol (3M3SH)) are secreted as cysteinylglycine conjugated peptides ([@bib74]; [@bib26]). *Staphylococcus hominis* transport and metabolise cysteinylglycine- 3-methyl-3-sulfanylhexan-1-ol (*S*-Cys-Gly-3M3SH) to liberate the odorous volatile 3M3SH, which is one of the major components of axillary malodour. (**B**) Chemical structure of the malodour precursor peptide, *S*-Cys-Gly-3M3SH. (**C**) Synthesis of *S*-Cys-Gly-3M3SH. *S*-Cys-Gly-3M3SH is derived from the glutathione 3-methyl-3-sulfanylhexanol conjugate (SG*-*3M3SH). SG*-*3M3SH is actively transported by the ATP-binding cassette transporter sub-family C member 11 (ABCC11) into apocrine secretory vesicles ([@bib8]). In the secretory vesicle, *S-*Gly*-*3M3SH is bio-transformed by *γ*-glutamyl transferase 1 (GGT1), which cleaves the terminal glutamyl residue generating S-Cys-Gly-3M3SH. S-Cys-Gly-3M3SH is secreted to the surface of the skin by apocrine secretion, which characteristically involves pinching off the apical cytoplasm and partial shedding releasing intracellular components into the luminal region of the apocrine gland. Upon release the cytoplasm may be recovered and repaired and a new cycle of secretion can occur ([@bib29]).](elife-34995-fig1){#fig1}

In humans, the link between the axillary apocrine gland, underarm bacteria and body odour (BO), was first recognised over 50 years ago ([@bib68]) and early culture-based studies on this relationship found the axillary microbiota to be dominated by Staphylococcus, Corynebacterium and Propionibacterium species, with the *Corynebacteria* in particular correlating with malodour intensity ([@bib77]; [@bib50]). More recent culture-independent meta-taxonomic studies have confirmed that the axilla is dominated by these genera, although the presence of additional taxa not previously indicated by culture-based methods is also evident, notably Gram-positive anaerobic cocci (GPAC) belonging to the *Anaerococcus* and *Peptoniphilus* genera ([@bib16]; [@bib23]; [@bib79]). Various molecules produced in the axilla have been linked to malodour, including 16-androstene steroids ([@bib36]) and short-chain (C2-C5) volatile fatty acids (VFAs) produced by axillary bacteria via several metabolic routes ([@bib47]). However, 16-androstenes are now believed to be only minor contributors to axillary malodour ([@bib46]), and it is accepted that the VFAs most heavily involved in BO are a series of structurally-unusual medium-chain (C6-C10) acids originating from *N*-acylglutamine precursors present in apocrine sweat ([@bib59]; [@bib58]). A third class of molecule, the thioalcohols (also called sulfanylalkanols), have recently been identified as important components of human body odour and a number of these have been detected within the volatiles released from the underarm ([@bib80]; [@bib60]; [@bib44]). They are particularly pungent and can be detected in pg.l^−1^ quantities, an order of magnitude lower than many other volatile chemicals emanating from the skin ([@bib60]). The most abundant and pungent of these thioalcohols is 3-methyl-3-sulfanylhexan-1-ol (3M3SH) ([Figure 1B](#fig1){ref-type="fig"}), which is a primary causal molecule of axillary malodour and subsequent BO ([@bib80]; [@bib44]).

Thioalcohols are known to be released as a peptide-conjugated precursor from the apocrine gland, which secretes directly into the hair follicle ([Figure 1A](#fig1){ref-type="fig"}). The biosynthetic origin of the thioalcohol precursors is currently poorly understood, but they are thought to be secreted into the axilla via the ABC transporter ABCC11 as odourless glutathione conjugates ([@bib7]). The glutathione conjugated form (SG-3M3SH) has never been detected in axillary sweat; however, the L-cysteinylglycine dipeptide conjugated form, S-\[1-(2-hydroxyethyl)−1-methylbutyl\]-L-cysteinylglycine (S-Cys-Gly-3M3SH) ([Figure 1B](#fig1){ref-type="fig"}), is readily detectable ([@bib74]) and recently a γ-glutamyl transferase (GGT1) has been demonstrated to localise to the apocrine sweat gland and convert SG-3M3SH to S-Cys-Gly-3M3SH ([@bib7]) ([Figure 1C](#fig1){ref-type="fig"}). We and others have demonstrated that S-Cys-Gly-3M3SH can be taken up and metabolised by a highly limited range of staphylococcal species present in the axilla, namely *Staphylococcus hominis*, *Staphylococcus haemolyticus* and *Staphylocooccus lugdunensis*, to liberate 3M3SH, that subsequently exits the cell through an undefined mechanism ([@bib80]; [@bib74]; [@bib9]). A strong correlation between *S. hominis* and body odour production has recently been established using culture-independent taxonomic studies of the axillary microbiota ([@bib79]), confirming the biological significance of this low-abundance species within the axilla in BO production in humans. However, the mechanism by which the S-Cys-Gly-3M3SH precursor molecule is taken up into *S. hominis* and related thioalcohol producers is currently unknown, hampering efforts to identify novel mechanisms to disrupt this process and control odour production in humans.

Here we identify the biochemical and structural basis for the recognition and specific transport of the malodour precursor peptide, S-Cys-Gly-3M3SH, into *S. hominis*. We first show that S-Cys-Gly-3M3SH is actively taken up by *S. hominis* through a specific secondary active transporter, STAH0001_1446 (SH1446), a member of the proton coupled oligopeptide transporter (POT) family ([@bib41]; [@bib66]). Through a combination of structural, biochemical and cell based assays we reveal how this peptide transporter is able to recognise a thioalcohol-conjugated peptide and further, show that transport is coupled to the inwardly directed proton electrochemical gradient. Our results suggest that SH1446 is a clear target for inhibitor design to prevent malodour production, thus providing further molecular insights into the role of the skin microbiota in human scent generation.

Results {#s2}
=======

POT transporters are essential for transport of thiol-conjugated dipeptides in *E. coli* {#s2-1}
----------------------------------------------------------------------------------------

To elucidate how thiol-conjugated dipeptides are transported by bacteria, we first examined the model organism *Escherichia coli*, which is able to recognise and metabolise the dipeptide version of the non-physiological malodour precursor *S*-benzyl-L-cysteine, namely, S-benzyl-L-cysteinylglycine ([@bib46]). Resting cells of *E. coli* were indeed able to remove S-benzyl-L-cysteinylglycine from solution and break it down to release the thiol active product, benzyl mercaptan ([Figure 2---figure supplement 1A,B](#fig2s1){ref-type="fig"}). Following transport into the cell, the dipeptide must be cleaved to release the benzyl mercaptan, most likely through a cysteine-*S*-conjugate β-lyase-type activity, for which a number have been described in *E. coli*, including MetC and MalY ([@bib22]; [@bib84]; [@bib4]). Interestingly, TnaA which is a tryptophanase known to have L-cysteine desulfhydrase activity ([@bib5]) is also capable of releasing benzyl mercaptan.

Individual disruption of *metC* and *malY* did not decrease the amount of benzyl mercaptan produced by *E. coli*, while disruption of *tnaA* led to an almost complete loss of biotransformation ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). This suggests that *E. coli* takes up the S-benzyl-L-cysteinylglycine, whereupon a host dipeptidase cleaves the glycine residue prior to cleavage of the *S*-benzyl-cysteine by TnaA to release the benzyl mercaptan.

To discover the genetic basis of the transport and metabolism of these thiol-conjugated dipeptides, we exploited the knock out (KO) library of single gene disruptions in *E. coli* K-12 ([@bib6]). We hypothesised that the dipeptide moiety might direct the molecule through a peptide transporter. In *E. coli* the main peptide systems are relatively well characterised, the two main transport systems belong to the ATP binding cassette (ABC) family and the proton dependent oligopeptide transporter (POT) family ([Figure 2B](#fig2){ref-type="fig"}). The *E. coli* Opp and Dpp ABC transporters have been extensively studied in *E. coli* and the closely related bacterium *Salmonella typhimurium* ([@bib72]; [@bib49]; [@bib1]; [@bib34]; [@bib76]) and an *E. coli* BW25113 strain with non-functional Opp and Dpp system (ΔDB1), was used to assess the role of these transporters in the production of benzyl mercaptan. Surprisingly, benzyl mercaptan production was similar to the wild-type strain, suggesting that neither ABC transporter was important for Cys-Gly-conjugate transport ([Figure 2A](#fig2){ref-type="fig"}). Having ruled out transport via the ABC peptide transporters, we then broadened our search to include additional peptide transporters that have been described in *E. coli*. These were the four members of the proton dependent oligopeptide transporter, or POT family, encoded by *dtpA-D*, that have poorly defined physiological roles during growth on peptides ([@bib42]; [@bib67]; [@bib12]), the CstA protein, orthologues of which have been demonstrated to be peptide transporters ([@bib32]) and the Sap system, which is implicated in uptake of cationic antimicrobial peptides ([@bib38]). Most of these strains had similar levels of benzyl mercaptan production to the wild-type, with the exception of *dtpB* which had an overall 50% drop in thiol production ([Figure 2A](#fig2){ref-type="fig"}). These data suggest that transporters belonging to the POT family are most likely responsible for Cys-Gly-conjugate transport, revealing a new biological role for bacterial POT transporters in the uptake of Cys-Gly-(S) conjugates.

![Biotransformation of both model (S-Benzyl-L-cysteinylglycine) and physiological substrate *S*-Cys-Gly-3M3SH by model organism *E.coli* K-12.\
(**A**) Biotransformation of S-Benzyl-L-cysteinylglycine by *E. coli* strains containing deletion in known or predicted peptide transporters. Strain ΔDB1 is an *oppA dppA* double mutant. Thioalcohol yield (A~492~) was quantified for each strain using MTS/PMS following 4 hr incubation. (**B**) Schematic overview of the main peptide transport systems in *E. coli*. (**C**) Biotransformation of *S*-Cys-Gly-3M3SH in *E. coli* K-12 overexpressing Dtp POT transporter proteins. (**D**) *S*-Cys-Gly-3M3SH biotransformation by *E. coli* K-12 overexpressing *S. hominis* STAHO0001_1446 (pSH1446) and STAHO0001_0415 (pSH0415). *E. coli* overexpressing *dtpB* (pDtpB) is shown for reference. Thioalcohol yield (A~412~) was quantified using DTNB after 24 hr incubation. Cultures with overexpressing plasmids were pre-induced with 0.0001% L-arabinose overnight. E. coli expressing pBADcLIC2005 with no gene insertion was included as a negative control (Empty vector). Error bars: ±SD (biological triplicates); \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001; One-way ANOVA followed by Dunnett's Multiple Comparison test.](elife-34995-fig2){#fig2}

Identification of a POT transporter from *S. hominis* that confers malodour production to *E. coli* {#s2-2}
---------------------------------------------------------------------------------------------------

Having established that *E. coli* has the ability to transport and cleave a Cys-Gly-(S) conjugated substrate, we reasoned that overexpression of a POT transporter might confer the ability to recognise the physiological malodour precursor S-Cys-Gly-3M3SH. The four *dtp* genes were cloned into a pBAD vector commonly used for overexpression of membrane transporters ([@bib55]; [@bib56]) and transformed into the wild-type *E. coli* background. The ability of the resulting strains to convert S-Cys-Gly-3M3SH to 3M3SH was subsequently measured ([@bib9]). Consistent with the reduction in benzyl mercaptan production reported in [Figure 2A](#fig2){ref-type="fig"}, the *dtpB* gene alone was able to confer a malodour production (BO^+^) phenotype to *E. coli*, which was not seen with any of the other *dtp* genes ([Figure 2C](#fig2){ref-type="fig"}). The same pattern was observed with S-benzyl-Cys-Gly as a substrate ([Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"}), suggesting that DtpB has a unique ability to transport these unusual conjugated peptides.

The molecular basis for S-Cys-Gly-3M3H transport into malodour producing staphylococci is unknown, and the genetic intractability of these poorly studied coagulase negative *Staphylococcal* species makes it difficult to study using genetic approaches. We therefore used an alternative approach exploiting our discovery that expression of a transporter in trans could produce a BO^+^ phenotype to *E. coli*. Given our discovery that *E. coli* POT family peptide transporters can transport S-Cys-Gly-3M3SH, we examined the genome of *S. hominis* SK1119, as *S. hominis* are the most abundant malodour producing Staphylococcal species in the underarm microbiota. Unlike *E. coli, S. hominis* contains only a single POT family member DtpT (SH1446), orthologues of which were seen in all sequenced staphylococci ([Figure 2---figure supplement 3A](#fig2s3){ref-type="fig"}). The POT peptide systems remain largely uncharacterised in staphyoloccci, although in the well-studied pathogen *S. aureus*, the single POT transporter encoded by *dtpT* is the sole route for dipeptide uptake in this species ([@bib45]). We also identified a second system, encoded by STAHO0001_0415 (SH0415), which is annotated as an MFS transporter and only present in *S. hominis* and *S. haemolyticus*, two known thioalcohol producers, and which is genetically linked to genes involved in peptide and amino acid metabolism ([Figure 2---figure supplement 3B](#fig2s3){ref-type="fig"}). Both transporters were cloned into pBADcLIC2005 and transformed into *E. coli* for functional analysis. When levels of 3M3SH production were measured in these strains, uptake was only enhanced by the presence of SH1446, with SH0415 having little effect on 3M3SH activity ([Figure 2D](#fig2){ref-type="fig"}). In contrast, with S-benzyl-cysteinlyglycine as a substrate, there was no increase in production of benzyl mercaptan with SH1446 but a significant increase was observed with SH0415 ([Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"}). Together these data strongly support the conclusion that the S-Cys-Gly-3M3SH transporter in *S. hominis* is the POT transporter STAH0001_1446 (SH1446).

To further demonstrate the importance of SH1446 in the physiological transport of *S-*Cys-Gly-3M3SH we used a biochemical approach to examine whether peptides could inhibit 3M3SH production by competing with *S-*Cys-Gly-3M3SH uptake. Firstly, we used our *E. coli* system where 3M3SH production is seen when SH1446 is expressed in trans and we observed clear inhibition of 3M3SH production with both di- and tri-Ala peptides ([Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}) but not with L-Ala alone nor tetra-Ala. The purified TnaA enzyme that cleaves Cys-3M3SH was not inhibited by any of these peptides ([Figure 2---figure supplement 5](#fig2s5){ref-type="fig"}) , supporting the hypothesis that the whole cell inhibition is due to inhibition of peptide transport. Similarly, we measured the ability of the same peptides to inhibit 3M3SH production directly in *S. hominis﻿* ([Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}*[﻿](#fig2s4){ref-type="fig"}*) and observed a comparable profile. It should be noted that a significant affect was observed for 25 mM tetra-Ala in *S. hominis* wild-type, however this affect is due to the acidic pH that was required to dissolve the peptide which appears to inhibit metabolism in *S. hominis* but not *E. coli*.

The *S. hominis* POT transporter, PepT~Sh~ transports *S*-Cys-Gly-3M3SH {#s2-3}
-----------------------------------------------------------------------

POT transporters belong to the Major Facilitator Superfamily (MFS) and use an inwardly directed proton electrochemical gradient to drive the concentrative uptake of di- and tri-peptides across the cell membrane for metabolic assimilation ([@bib17]). To establish SH1446 as the protein responsible for S-Cys-Gly-3M3SH recognition and transport, the gene was cloned and overexpressed in *E. coli* for functional and structural studies. The purified protein, hereafter referred to as PepT~Sh~ (Peptide Transporter *Staphylococcus hominis*) was purified and reconstituted into liposomes. Transport was studied using a previously employed pyranine based reporter assay, which measures transport via changes to the internal pH of the liposomes ([@bib65]) ([Figure 3A](#fig3){ref-type="fig"}). Acidification of the lumen of the liposome was observed in the presence of a membrane potential (ΔΨ, negative inside), and addition of external di- or tri-peptide substrate, demonstrating that PepT~Sh~ is a proton coupled peptide transporter. Importantly we also observed acidification in the presence of the S-Cys-Gly-3M3SH precursor peptide, confirming our earlier identification of PepT~Sh~ as the transporter for this molecule in *S. hominis*.

![Functional characterisation of PepT~Sh~.\
(**A**) Monitoring proton coupled peptide uptake using a pH sensitive dye. PepT~Sh~ was reconstituted into liposomes loaded with pyranine and a high concentration of potassium ions. The external solution contains either peptide, Ala-Ala (orange), Ala-Ala-Ala (purple), Cys-Gly (Green) or S-Cys-Gly-3M3SH (red) and a low potassium concentration. On addition of valinomycin (V) the membrane becomes highly permeable to potassium, generating a hyperpolarised membrane potential (negative inside), which drives the uptake of protons and ligand, protonating the pyranine dye and altering its fluorescent properties. A change in the ratio of fluorescence demonstrates active transport of the ligand. (**B**) Representative IC~50~ curves showing the relative affinity of the different ligands shown in A for PepT~Sh.~ Assays were set up to measure the ability of competitor peptides to reduce uptake of tritiated di-Alanine (AA) peptide.](elife-34995-fig3){#fig3}

To understand the recognition of S-Cys-Gly-3M3SH compared to natural peptides, we determined IC~50~ values using competition with ^3^H-di-alanine. The IC~50~ value for tri-alanine, di-alanine and Cys-Gly were 23.7 ± 3.4, 72.2 ± 9.7 and 115 ± 22.2 μM, respectively ([Figure 3B](#fig3){ref-type="fig"}), indicating that PepT~Sh~ is able to recognise tri-Ala more favourably than di-Ala. However, for S-Cys-Gly-3M3SH the IC~50~ value was 362 ± 21.8 μM, three-fold higher than the Cys-Gly peptide. Our data therefore show that while PepT~Sh~ can transport the modified peptide, the addition of the thioalcohol group on the cysteine side chain has substantially impaired the recognition and transport versus natural peptides.

Crystal structure of PepT~Sh~ bound to *S*-Cys-Gly-3M3SH {#s2-4}
--------------------------------------------------------

To gain further insight into the mechanism of substrate binding we successfully obtained a high-resolution co-crystal structure of PepT~Sh~ at 2.5 Å resolution, bound to S-Cys-Gly-3M3SH using the *in meso* crystallisation method ([Figure 4A](#fig4){ref-type="fig"}, [Table 1](#table1){ref-type="table"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). PepT~Sh~ adopts the canonical MFS fold with helices H1-H6 forming the N-terminal bundle and H7-H12 the C-terminal bundle. PepT~Sh~ was crystallised in an inward open state, observed previously for other members of the POT family ([@bib62]), wherein the extracellular gate, consisting of helices H1-2 and H7-8 from the N- and C-terminal bundles respectively, is closed and the intracellular gate, consisting of helices H4-5 and H10-11 is open. Similar to other bacterial POT family members, PepT~Sh~ contains two additional helices inserted between the N- and C-terminal bundles, termed HA and HB ([Figure 4B](#fig4){ref-type="fig"} and [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). Unlike previous POT structures however, PepT~Sh~ also contains a well-structured β-hairpin motif between helices H7 and H8 on the extracellular side of the membrane, extending out in line with the lipid head groups. Interestingly we observed a number of monoolein lipid molecules that cluster around both the β- hairpin and the cavity created between helices HA and HB with the transporter domain. The role of helices HA and HB in prokaryotic POT family transporters still remains unclear. However, the observation of lipid molecules bound between these helices and the transport domain suggests a possible role in stabilising these transporters in the membrane, which may be an adaption specific to prokaryotic members of the POT family ([@bib61]).

![Crystal structure of PepT~Sh~.\
(**A**) Crystal structure of PepT~Sh~ shown in the plane of the membrane. Transmembrane helices making up the N-terminal bundle, H1-H6, are coloured green and pack against the C-terminal bundle, helices H7-H12. The bound S-Cys-Gly-3M3SH peptide is shown in sticks. (**B**) View of A rotated 90 °. The additional helices, HA and HB, can be clearly observed packing to one side of the transporter. The bound lipids are shown as spheres. (**C**) Zoomed in view of the binding site showing the bound S-Cys-Gly-3M3SH ligand with the mFo-DFc difference electron density map contoured at 3 σ in green mesh. (**D**) Equivalent view of the binding site showing the location of ordered water molecules in the binding site. (**E**) View showing the electrostatic surface of the binding site of the transporter with the hydrophobic pocket accommodating the acyl chain of the ligand.](elife-34995-fig4){#fig4}
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###### Data collection and refinement statistics.

Statistics for the highest-resolution shell are shown in parentheses.

  ---------------------------------------------------------------------
                                   PepT~Sh~\
                                   (PDB: 6EXS)
  -------------------------------- ------------------------------------
  Wavelength                       0.8729

  Resolution range                 45.1--2.5 (2.589--2.5)

  Space group                      P 1 21 1

  Unit cell                        60.04 55.576 100.866 90 104.749 90

  Total reflections                151797 (14474)

  Unique reflections               22501 (2204)

  Multiplicity                     6.7 (6.6)

  Completeness (%)                 99.43 (99.73)

  Mean I/sigma (I)                 9.76 (1.48)

  Wilson B-factor                  43.87

  R-merge                          0.159 (1.28)

  R-meas                           0.172 (1.39)

  R-pim                            0.07 (0.54)

  CC1/2                            0.997 (0.59)

  CC\*                             0.999 (0.86)

  Reflections used in refinement   22504 (2204)

  Reflections used for R-free      1137 (110)

  R-work                           0.21 (0.21)

  R-free                           0.23 (0.24)

  CC (work)                        0.88 (0.69)

  CC (free)                        0.85 (0.52)

  Number of non-hydrogen atoms     4063

  macromolecules                   3614

  ligands                          384

  solvent                          65

  Protein residues                 487

  RMS(bonds)                       0.01

  RMS(angles)                      1.04

  Ramachandran favored (%)         98.35

  Ramachandran allowed (%)         1.65

  Ramachandran outliers (%)        0

  Rotamer outliers (%)             1.47

  Clashscore                       2.59

  Average B-factor                 57.0

  macromolecules                   54.72

  ligands                          80.53

  solvent                          51.2
  ---------------------------------------------------------------------

Following extensive screening and co-crystallisation we observed clear m*F*~o~-D*F*~c~ difference electron density for the S-Cys-Gly-3M3SH ligand in the peptide binding site ([Figure 4C](#fig4){ref-type="fig"} and [Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). The Cys-Gly part of the precursor is positioned such that the carboxy termini of the peptide faces towards the intracellular side of the binding site. The terminal carboxyl group makes two hydrogen bond interactions, one with Tyr41 on H1 and a second interaction to a water molecule (W107), which links the carboxyl group with Asn347 on H8. The carbonyl group of the CG peptide also makes a hydrogen bond to this water molecule, creating a well-coordinated interaction network between the peptide and Asn347 ([Figure 4D](#fig4){ref-type="fig"}). The terminal amino group makes two further polar interactions, with a water molecule that sits next to Tyr41 and also to the carbonyl group of Gln344, which sits further up on H8. In contrast, the thioalcohol moiety points towards the extracellular gate, with the sulphur atom sitting close to Gln310 on H7, whereas the alcohol group extends towards helix H8 making interactions with backbone carbonyl and amide groups of Phe343 and Asn347, respectively. The acyl group extends into a large pocket nestled between helices H7 and H10 ([Figure 4E](#fig4){ref-type="fig"}). This long pocket (\~10 Å) extends from the central peptide binding site into the C-terminal bundle of the transporter and is both hydrophobic and polar in character.

Previously, we showed that a related POT family transporter, PepT~St~, is able to bind peptides in different orientations in the binding site, with a di-peptide adopting a horizontal position and a tri-peptide a vertical one ([@bib51]) and suggested this flexibility may be responsible for the accomodation of larger peptide ligands ([@bib63]). Here we see that the *S-*Cys-Gly-3M3SH peptide adopts a more vertical orientation, similar to the tri-alanine position in PepT~St~. However, there are significant differences in the interactions. A structural overlay of the *S-*Cys-Gly-3M3SH peptide shows that it sits much further up in the binding site compared to the natural peptides captured in PepT~St~ ([Figure 4---figure supplement 4A & B](#fig4s4){ref-type="fig"}), most likely as a result of the requirement to accommodate the thioalcohol group in the extended pocket. This has a knock-on effect with respect to the position of the amino and carboxy termini. In PepT~St~, the amino terminal group of the di-peptide directly interacts with helix H8 and H10, whereas the tri-peptide makes a much weaker interaction through a carbonyl group. In contrast, in PepT~Sh ~this interaction is achieved through a water mediated hydrogen bond ([Figure 4D](#fig4){ref-type="fig"}).

The role of water in mediating interactions between peptides and their binding sites has been previously observed in the ABC transporter binding domains ([@bib76]), albeit for side chain independent binding. A similar mechanism may be employed by PepT~Sh~ to facilitate transport of modified peptides by replacing direct interactions between the peptide and the transporter when these are sterically restricted, as we observe with *S-*Cys-Gly-3M3SH. The interaction of the amino termini of peptides with both the mammalian and bacterial POT family transporters has been identified as facilitating high affinity binding ([@bib82]; [@bib53]). The reduced IC~50~ value for the modified peptide in PepT~Sh~ ([Figure 3B](#fig3){ref-type="fig"}), may therefore be a combination of steric restraints resulting in the accommodation of the extended side chain group, and the subsequent knock on effects on the position of the interactions between the amino and carboxy groups with conserved side chains in the binding site.

Functional characterisation of PepT~Sh~ binding site {#s2-5}
----------------------------------------------------

S-Cys-Gly-3M3SH is the first human derived peptide with a modified side chain to be captured in a POT family transporter, and contains biochemical features similar to physiological peptides (Cys-Gly), but also incorporates the non-peptide thioalcohol group (3M3SH). We therefore wished to explore whether S-Cys-Gly-3M3SH is recognised using a similar mechanism to physiological peptides. Several mutations in the binding site that have previously been shown to play an important role in peptide recognition within the bacterial POT family were therefore generated ([@bib63]). Tyrosine 41 forms part of a conserved E^33^xxERFxYY^41^ motif on TM1 ([@bib73]), which plays a role in proton coupling and influences peptide uptake in several POT family members ([@bib19]; [@bib27]; [@bib39]; [@bib51]). In PepT~Sh~ Tyr41 hydrogen bonds with the carboxyl terminus of the terminal glycine amino acid in S-Cys-Gly-3M3SH ([Figure 4C,D](#fig4){ref-type="fig"}). Mutating Tyr41 to phenylalanine or alanine severely reduced transport of di-alanine compared to WT protein ([Figure 5A](#fig5){ref-type="fig"}). A similar negative effect on transport was observed in the related POT family transporter PepT~St~, from *Streptococcus thermophilus* ([@bib73]), suggesting a common role for the conserved tyrosine in peptide recognition within the POT family. We then used the same variants in our whole cell assay for 3M3SH production. Interestingly, while both Tyr41Phe and Tyr41Ala variants had reduced activity, at about 50% of the wild-type protein ([Figure 5B](#fig5){ref-type="fig"}), the phenotype was not as severe as that observed in the liposome based assay. We interpret this result to indicate that recognition of *S-*Cys-Gly-3M3SH is less dependent on this residue than di-Ala.

![Functional characterisation of binding site residues.\
(**A**) Bar chart showing the di-alanine uptake for the WT and mutant variants of PepT~Sh~. Inset -- SDS-PAGE analysis of the reconstituted proteins used in the assay. (**B**) Biotransformation of *S*-Cys-Gly-3M3SH by *E. coli* K-12 (BW25113) overexpressing WT PepT~St~ (pBAD_1446), or variants indicated, compared to background uptake in non-transformed cells (WT BW25113) and cells harbouring empty plasmid (pBAD-EmptyVector). Error bars: ±SD (biological triplicates).](elife-34995-fig5){#fig5}

We next wanted to test the role of other residues we observed sitting close to the S-Cys-Gly-3M3SH ligand. In particular, we were interested in the contribution made by the Asn347 and Glu418, which coordinate a water molecule (W107) linking both the carboxyl and carbonyl groups of the ligand to the binding site ([Figure 4B](#fig4){ref-type="fig"}). The equivalent residues in homologous POT family transporters have been implicated in both peptide recognition ([@bib51]) and gating ([@bib73]), and in the case of Glu418 may facilitate the coupling between peptide recognition, proton movement and transport ([@bib64]). Although a Glu418Ala variant had no activity in our assays, consistent with its proposed role in coordinating the intracellular gate ([@bib30]), we observed reduced uptake of di-Ala in the Asn347Ala variant ([Figure 5A](#fig5){ref-type="fig"}). Interestingly, this reduction was far more severe in the in vivo assay ([Figure 5B](#fig5){ref-type="fig"}), indicating that this interaction is more important for transport of the S-Cys-Gly-3M3SH peptide than di-Ala. This may reflect the requirement of Asn347 to coordinate the water molecule linking the peptide to the intracellular gate side chain Glu418, which in the case of the di-peptide may interact directly as in PepT~St~, lessening the requirement for the Asn347 interaction.

The co-crystal structure also identified the acyl chain portion of the thioalcohol group was accommodated within an extended pocket, formed near the extracellular side of the binding site ([Figure 4E](#fig4){ref-type="fig"}). To test the importance of this pocket on *S-*Cys-Gly-3M3SH transport, we made a Tyr411Trp variant, which would block the cavity. Uptake was noticeably reduced, but still measurable at \~19% compared to WT ([Figure 5A](#fig5){ref-type="fig"}). The same mutation resulted in a similar large decrease in the biotransformation of *S-*Cys-Gly-3M3SH, while a Tyr411Ala mutation had wild-type biotransformation rates ([Figure 5B](#fig5){ref-type="fig"}). It is clear that the hydrophobic pocket in PepT~Sh~ plays an important role in facilitating the recognition of the thioalcohol group in the binding pocket and, as discussed below, is a potential site for inhibitor design.

Taken together the current data lend further support to our model of an adaptable binding site within the POT family that can accommodate chemically diverse peptides and their derivatives through the use of both side chain and water mediated interactions with conserved residues and different specificity pockets to accommodate the different chemical side chains.

Discussion {#s3}
==========

The production of malodour by humans is an evolutionary ancient olfactory process that likely was involved in mate selection and evolutionary processes that relied on chemical signalling ([@bib75]). Evidence for the microbial origins of chemical signalling molecules is also seen in other animals such as foxes, deer, cats and beetles ([@bib83]), but the details of this process in humans is less well understood. The thioalcohol 3M3SH, a major component of body odour, is produced in the human axilla as a glutathione-conjugated precursor and is processed to a unique dipeptide structure ([Figure 1](#fig1){ref-type="fig"}). The discovery that axilla-isolated strains of *S. hominis*, *S. lugdunensis* and *S. heamolyticus* are able to produce 3M3SH prompted the search for the molecular basis for this process ([@bib9]). While S-Cys-Gly-3M3SH is a highly modified and uniquely human dipeptide, we reasoned that this moiety might dictate the uptake mechanism into malodour producing bacteria and here we identify a peptide transporter, PepT~Sh~ (SH1446), from the POT family of secondary active transporters as being responsible for this process. Each of these strains have a POT family transporter that is closely related to PepT~Sh~ ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}), and we would predict they will also be able to uptake S-Cys-Gly-3M3SH.

The genetic intractability of *S. hominis* dictated that we use a biochemical approach to demonstrate that SH1446 is likely the sole route of uptake of S-Cys-Gly-3M3SH. First, this staphylococci has a similar repertoire of peptide transporters in *S. aureus*, in that it has a single POT transporter and one Opp ABC transporter, and previous work in *S. aureus* has demonstrated that the POT transporter, DtpT, is essential for growth on dipeptides and some tripeptides, while the ABC transporter (Opp3) has a function in transporting longer oligopeptides ([@bib45]). The use of L-Ala containing peptides as inhibitors in this study demonstrates an inhibitory effect on 3M3SH production that is consistent with the properties of a POT family transporter. Several attempts were made to genetically disrupt SH1446 in *S. hominis*, using tools developed for *S. aureus* and *S. epidermidis*, but these were unsuccessful, most likely due to the presence of multiple species-specific restriction modification (RM) systems which render this organism, as with many other coagulase negative (CoNS) species, genetically intractable.

The specific role for POT transporters in the transport of these unusually modified dipeptides is supported from the inability of the *E. coli* ABC transporters for oligopeptides and dipeptides, Opp and Dpp, to recognise and transport S-Cys-Gly-3M3SH. Given that S-Cys-Gly-3M3SH is effectively a dipeptide with a highly extended R-group on the first amino acid, it is noteworthy that only the promiscuous nature of the POT binding site is able to recognise this ligand. For OppA and DppA, the substrate binding proteins that initially recognise peptides transported by the ABC systems, the binding pocket is well defined and makes general main chain-main chain interactions to ensure that the protein can bind peptides in a sequence independent manner ([@bib76]; [@bib70]; [@bib69]). However, the pocket has evolved to accommodate regular amino acid side chains and the unusually large structure of the thioalcohol attachment would likely be sterically incompatible with recognition by either OppA or DppA. The data presented here further support the idea that POT transporters have an unusually promiscuous binding site that may play an evolutionary advantageous role in accepting modified peptides as substrates.

Recently, the human POT family transporters, PepT1 and PepT2, have gained additional attention due to their role in the absorption and retention of several important classes of drug molecule ([@bib71]), including peptide modified pro-drugs. Similar to S-Cys-Gly-3M3SH, these pro-drugs are drug molecules conjugated to a peptide or amino acid ([@bib11]). Pro-drugs are able to compete with natural peptides for transport via PepT1 and PepT2, and are therefore actively transported into the body ([@bib31]; [@bib40]; [@bib78]). The promiscuous nature of the POT family binding site has been shown to derive, in part, from their ability to recognise peptides in different conformations and through the availability of different specificity pockets, which are able to accommodate chemically different classes of peptides ([@bib63]). Our results here provide the first evidence that specificity pockets can also accommodate exotic chemical extensions. The observation that water plays a role in facilitating the interaction between the S-Cys-Gly-3M3SH peptide and PepT~Sh~ may also indicate a broader role for water in facilitating the recognition of xenobiotic peptides. In particular, the observation that water may bridge interactions between the binding site and either the amino or carboxy group of the ligand would greatly increase the number of conformations a peptide could adopt in the transporter and still trigger proton coupled transport.

Finally, we can ask the questions, why do these bacteria transport S-Cys-Gly-3M3SH and can this process be inhibited to provide effective malodour control? The presumed biochemical pathway for breakdown of the S-Cys-Gly-3M3SH is outlined in [Figure 6](#fig6){ref-type="fig"}. The firststep is the likely removal of the glycine by a dipeptidase and then the lyase reaction that cleaves the carbon-sulphur bond to release pyruvate and ammonia in addition to 3M3SH. The route of export of 3M3SH is unknown, but currently assumed to be diffusion across the bacterial inner membrane. The bacterium will gain a nutritional benefit from the catabolism of S-Cys-Gly-3M3SH via the release of both nitrogen and carbon as glycine, pyruvate and ammonia ([Figure 6](#fig6){ref-type="fig"}), which may have been the evolutionary trigger for the adaptation to catabolise this chemical. Asian individuals with single nucleotide polymorphisms (SNPs) in ABCC11, the transporters involved in the secretion of S-Cys-Gly-3M3SH ([Figure 1](#fig1){ref-type="fig"}) have been studied ([@bib57]; [@bib8]). Recently, a microbiological investigation of individuals with wild-type alleles of *ABCC11* compared to heterozygous and double mutant genotypes revealed that the proportion of *Staphylococcus* sp. is higher in the underarms of humans that produce the precursor ([@bib43]). While these studies are limited in that they do not provide species level identification, they are at least consistent with the idea that the production of the precursor positively correlates with the presence of *Staphylococcus* sp. in the underarm. The discovery of the transporter and molecular understanding of the mode of S-Cys-Gly-3M3SH binding now suggests a specific route to develop inhibitors of malodour production by directly inhibiting the transporter SH1446 ([@bib37]). Importantly, such intervention would not impact on the overall axillar microbiome, but instead specifically target the reduction in body odour production.

![Overview of transport and intracellular biotransformation of *S*-Cys-Gly-3M3SH in *Staphylococcus hominis*.\
1. Cys-Gly-(*S*)−3M3SH is actively transported across the membrane by the di/tri peptide transporter PepT~Sh~ along with the movement of protons. 2. A dipeptidase cleaves the terminal glycine residue of *S*-Cys-Gly-3M3SH producing Cys-(*S*)−3M3SH. 3. The thiol is liberated from Cys-(S)−3M3SH by a C-S β-lyase that also releases ammonia and pyruvate, the volatile thiol (3M3SH) then diffuses or is exported out the cell. 4.](elife-34995-fig6){#fig6}

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\           Designation                   Source or reference                                                 Identifiers               Additional\
  (species) or resource                                                                                                                               information
  ----------------------- ----------------------------- ------------------------------------------------------------------- ------------------------- ----------------------------
  Ggene\                  *dtpA*                        BW25113                                                             b1634, ECK1630            POT transporter\
  (*Escherichia coli*)                                                                                                                                family

  Gene\                   *dtpB*                        BW25113                                                             b3496, ECK3481            POT transporter\
  (*Escherichia coli*)                                                                                                                                family

  Gene\                   *dtpC*                        BW25113                                                             b4130, ECK4124            POT transporter\
  (*Escherichia coli*)                                                                                                                                family

  Gene\                   *dtpD*                        BW25113                                                             b0709, ECK0698            POT transporter\
  (*Escherichia coli*)                                                                                                                                family

  Gene\                   *tnaA*                        BW25113                                                             b3708, ECK3701            Tryptophanase
  (*Escherichia coli*)                                                                                                                                

  Gene\                   *SH1446*                      SK119                                                               STAHO0001_1446\           POT transporter\
  (*Staphylococcus*\                                                                                                        (GenBank: EEK12089.1)     family
  *hominis*)                                                                                                                                          

  Gene\                   *SH0415*                      SK119                                                               STAHO0001_0415\           MFS transporter\
  (*Staphylococcus*\                                                                                                        (GenBank: EEK11635.1)     family
  *hominis*)                                                                                                                                          

  Strain, strain\         BW25113                       [@bib6]                                                                                       F-, Δ(*araD-araB*)567,\
  background\                                                                                                                                         Δl*acZ*4787(::*rrnB*-3),\
  (*Escherichia coli*)                                                                                                                                lambda-, rph-1,\
                                                                                                                                                      Δ(*rhaD-rhaB*)568,\
                                                                                                                                                      *hsdR*514

  Strain, strain\         JW1237                        [@bib6]                                                                                       *ΔoppC::kanR*
  background\                                                                                                                                         
  (*Escherichia coli*)                                                                                                                                

  Strain, strain\         JW3511                        [@bib6]                                                                                       *ΔdppC::kanR*
  background\                                                                                                                                         
  (*Escherichia coli*)                                                                                                                                

  Strain, strain\         JW1626                        [@bib6]                                                                                       *ΔdtpA::kanR*
  background\                                                                                                                                         
  (*Escherichia coli*)                                                                                                                                

  Strain, strain\         JW3463                        [@bib6]                                                                                       *ΔdtpB::kanR*
  background\                                                                                                                                         
  (*Escherichia coli*)                                                                                                                                

  Strain, strain\         JW4091                        [@bib6]                                                                                       *ΔdtpC::kanR*
  background\                                                                                                                                         
  (*Escherichia coli*)                                                                                                                                

  Strain, strain\         JW0699                        [@bib6]                                                                                       *ΔdtpD::kanR*
  background\                                                                                                                                         
  (*Escherichia coli*)                                                                                                                                

  Strain, strain\         JW3686                        [@bib6]                                                                                       *ΔtnaA::kanR*
  background\                                                                                                                                         
  (*Escherichia coli*)                                                                                                                                

  Strain, strain\         JW2975                        [@bib6]                                                                                       *ΔmetC::kanR*
  background\                                                                                                                                         
  (*Escherichia coli*)                                                                                                                                

  Strain, strain\         JW1614                        [@bib6]                                                                                       *ΔmalY::kanR*
  background\                                                                                                                                         
  (*Escherichia coli*)                                                                                                                                

  Strain, strain\         JW1285                        [@bib6]                                                                                       *ΔsapC::kanR*
  background\                                                                                                                                         
  (*Escherichia coli*)                                                                                                                                

  Strain, strain\         JW0590                        [@bib6]                                                                                       *ΔcstA::kanR*
  background\                                                                                                                                         
  (*Escherichia coli*)                                                                                                                                

  Strain, strain\         ΔoppC                         This study. KanR\                                                                             *ΔoppC*
  background\                                           removed from parent strain                                                                    
  (*Escherichia coli*)                                                                                                                                

  Strain, strain\         ΔdppC                         This study. KanR\                                                                             *ΔdppC*
  background\                                           removed from parent strain                                                                    
  (*Escherichia coli*)                                                                                                                                

  Strain, strain\         ΔdtpA                         This study. KanR\                                                                             *ΔdtpA*
  background\                                           removed from\                                                                                 
  (*Escherichia coli*)                                  parent strain                                                                                 

  Strain, strain\         ΔdtpB                         This study. KanR\                                                                             *ΔdtpB*
  background\                                           removed from\                                                                                 
  (*Escherichia coli*)                                  parent strain                                                                                 

  Strain, strain\         ΔdtpC                         This study. KanR\                                                                             *ΔdtpC*
  background\                                           removed from\                                                                                 
  (*Escherichia coli*)                                  parent strain                                                                                 

  Strain, strain\         ΔdtpD                         This study. KanR\                                                                             *ΔdtpD*
  background\                                           removed from\                                                                                 
  (*Escherichia coli*)                                  parent strain                                                                                 

  Strain, strain\         ΔtnaA                         This study. KanR\                                                                             *ΔtnaA*
  background\                                           removed from\                                                                                 
  (*Escherichia coli*)                                  parent strain                                                                                 

  Strain, strain\         ΔDB1                          This study. KanR\                                                                             *ΔoppC ΔdppC*
  background\                                           removed from\                                                                                 
  (*Escherichia coli*)                                  parent strain                                                                                 

  Strain, strain\         SK119                                                                                             Taxonomy ID: 629742\      
  background\                                                                                                               (Accession: PRJNA34087)   
  (*Staphylococcus*\                                                                                                                                  
  *hominis*)                                                                                                                                          

  Strain, strain\         C43(DE3)                      [@bib54]                                                                                      
  background                                                                                                                                          

  Strain, strain\         pWaldo-GFPe                   [@bib21]                                                                                      
  background                                                                                                                                          

  Genetic\                pBADcLIC2005                  [@bib33]                                                                                      pBAD vector modified\
  reagent\                                                                                                                                            with LIC cassette, P~BAD~
  (Escherichia coli)                                                                                                                                  

  Genetic\                pKD46                         [@bib18]                                                                                      Contains Kan^R^\
  reagent\                                                                                                                                            cassette
  (Escherichia coli)                                                                                                                                  

  Genetic\                pCP20                         [@bib14]                                                                                      FLP^+^, pSC101 origin,\
  reagent\                                                                                                                                            λ cI857+, λ p~R~ Rep^ts^,\
  (Escherichia coli)                                                                                                                                  Amp^R^, Cm^R^

  Recombinant\            pBADcLIC-dtpA                 This study. Cloned\                                                                           
  DNA reagent                                           using primers in\                                                                             
                                                        [Supplementary file 1](#supp1){ref-type="supplementary-material"}                             

  Recombinant\            pBADcLIC-dtpB                 This study. Cloned\                                                                           
  DNA reagent                                           using primers in\                                                                             
                                                        [Supplementary file 1](#supp1){ref-type="supplementary-material"}                             

  Recombinant\            pBADcLIC-dtpC                 This study. Cloned\                                                                           
  DNA reagent                                           using primers in\                                                                             
                                                        [Supplementary file 1](#supp1){ref-type="supplementary-material"}                             

  Recombinant\            pBADcLIC-dtpD                 This study. Cloned\                                                                           
  DNA reagent                                           using primers in\                                                                             
                                                        [Supplementary file 1](#supp1){ref-type="supplementary-material"}                             

  Recombinant\            pBADcLIC-SH0415               This study. Cloned\                                                                           
  DNA reagent                                           using primers in\                                                                             
                                                        [Supplementary file 1](#supp1){ref-type="supplementary-material"}                             

  Recombinant\            pBADcLIC-SH1446               This study. Cloned\                                                                           
  DNA reagent                                           using primers in\                                                                             
                                                        [Supplementary file 1](#supp1){ref-type="supplementary-material"}                             

  Peptide,\               SH1446                        This study. Purified from\                                                                    
  recombinant protein                                   *E. coli* BW25113\                                                                            
                                                        containing pBADcLIC-SH1446                                                                    

  Peptide,\               TnaA                          This study. Purified from\                                                                    
  recombinant protein                                   *E. coli* BW25113\                                                                            
                                                        containing pBADcLIC-TnaA                                                                      

  Chemical\               S-Cys-Gly-3M3SH               Peakdale Molecular (UK)                                                                       Custom made\
  compound, drug                                                                                                                                      malodour substrates

  Chemical\               L-Ala                         Sigma-Aldrich\                                                      A7627                     
  compound, drug                                        (St. Louis, MO, USA)                                                                          

  Chemical\               L-Ala-Ala                     Sigma-Aldrich\                                                      A9502                     
  compound, drug                                        (St. Louis, MO, USA)                                                                          

  Chemical\               L-Ala-Ala-Ala                 Sigma-Aldrich\                                                      A9627                     
  compound, drug                                        (St. Louis, MO, USA)                                                                          

  Chemical\               L-Ala-Ala-Ala-Ala             Cambridge Biosciences                                               H-1260.0250               
  compound, drug                                                                                                                                      

  Chemical\               n-Decyl-β-D-maltopyranoside   Anatrace                                                            D322LA                    
  compound, drug                                                                                                                                      

  Chemical\               n-Dodecyl-β-D-maltoside       Anatrace                                                            D310LA                    
  compound, drug                                                                                                                                      

  Chemical\               Nickel-NTA Superflow resin    ThermoFisher                                                        88221                     
  compound, drug                                                                                                                                      
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Bacterial strains, media and plasmids {#s4-1}
-------------------------------------

*Escherichia coli* K-12 was used as the model organism throughout this study. *Escherichia coli* K-12 single gene deletions were obtained from the in-house *E. coli* Keio collection at University of York. Bacterial strains and plasmids used in this study are listed in [Supplementary file 1](#supp1){ref-type="supplementary-material"} and [2](#supp2){ref-type="supplementary-material"}. All strains were cultured in LB (1% tryptone, 0.5% yeast extract, 1% NaCl) unless otherwise stated, Antibiotics were used at the following concentrations Ampicillin 100 μg/mL and Kanamycin 50 μg/mL; L-arabinose concentrations are indicated. PCR, plasmid extractions, and transformations were carried out as per standard protocols. For routine cloning, genomic DNA was extracted from BW25113 and high fidelity KOD polymerase was used (Novagen). Correct clones were confirmed by DNA sequencing. Specific details of plasmid constructions are detailed below.

Construction of multiple mutants in single keio deletions {#s4-2}
---------------------------------------------------------

Multiple gene knockouts were created in single keio deletion strains. To create the double KO strain DB1 (Δ*oppC* Δ*dppC*), the Kan^R^ cassette was removed from a target gene using pCP20 (encoding Flp recombinase) at 30°C, loss of antibiotic cassette was confirmed by PCR and sequencing. The second gene to be disrupted was PCR amplified with 100 bp homology including the FRT flanked Kan^R^ cassette from the single gene deletion strain in the keio collection. Targeted gene disruptions were created using λ Red recombination as previously described ([@bib18]).

Plasmid constructions and protein purification: pBAD-dtpA, dtpB, dtpC, dtpC, tnaA {#s4-3}
---------------------------------------------------------------------------------

Overexpression of the *E. coli* POT transporters were cloned into pBADcLIC2005 vector under the control of arabinose. Full-length genes were amplified from *E. coli* BW25113 genomic DNA using high fidelity KOD polymerase (Merck) using the corresponding primers listed in [Supplementary file 3](#supp3){ref-type="supplementary-material"}. In silico analysis of the available *Staphylococcus hominis* SK1119 genome identified STAH0001_1446 (SH1446) as a POT family member which orthologues present in all sequenced staphylococci and a MFS transporter STAH0001_0415 (SH0415) present in only *S. hominis* and *S. haemolyticus*. SH0415 and SH1446 genes were amplified from *S. hominis* genomic DNA using high fidelity KOD polymerase (Merck) using primers listed in [Supplementary file 3](#supp3){ref-type="supplementary-material"}. All PCR products were purified using Wizard SV Gel and PCR Clean-Up System (Promega), cloned into pBADcLIC2005 vector using standard ligation-independent cloning (LIC) techniques. All fragments were confirmed by PCR and DNA sequencing (GATC Biotech).

Site directed mutagenesis of SH1446 {#s4-4}
-----------------------------------

The wildtype STAHO0001_1446 (SH1446) cloned onto the expression plasmid pBADcLIC2005 was used to individually generate the Y411W, Y411A, Y41A, Y41F, N167A and N347A mutants. To introduce the mutation, high fidelity inverse PCR was performed using divergent primers with one per pair being mutagenic ([Supplementary file 3](#supp3){ref-type="supplementary-material"}). The resultant products were then circularised by performing a blunt end ligation and transformed into *E. coli* BW25113. The mutant sequences were verified by DNA sequencing (GATC Biotech).

Malodour precursor biotransformation assay malodour precursor substrates {#s4-5}
------------------------------------------------------------------------

S-Benzyl-L-cysteinylglycine and (S)-(1-(2-hydroxyethyl)−1-methylbutyl)-L-cysteinylglycine (S-Cys-Gly-3M3SH) (Peakdale Molecular) were prepared at a stock concentration of 10 mM in M9 salts (6 g Na~2~HPO~4~ g/L, 3 g KH~2~PO~4~ g/L, 0.5 g NaCl g/L) and stored at 4°C.

S-Benzyl-L-cysteinylglycine and S-Cys-Gly-3M3SH biotransformation assays using resting cells {#s4-6}
--------------------------------------------------------------------------------------------

*E. coli* were grown overnight in LB, cells were harvested by centrifugation at 3, 500 rpm 10 min and resuspended in sterile M9 salts. Where appropriate, *E. coli* strains harbouring inducible genes on the pBADcLIC2005 plasmid were pre-induced during overnight growth with 0.0001% L-arabinose. To a sterile Eppendorf the following was added; 2 mM substrate (*S*-Benzyl-L-cysteinylglycine or *S*-Cys-Gly-3M3SH), cells to an OD~650nm~ of 5 and M9 salts up to 200 μL. Cells only (no added substrate) and substrate only (no added cells) reactions were also included in every individual experiment. The reactions were incubated at 37°C for up to 48 hr with samples taken at appropriate time points. Liberated thiols were quantified using either MTS/PMS or DTNB labelling as detailed below.

(3-(4,5-dimethylthiazol-2-yl)−5-(3-carboxymethoxyphenyl)−2-(4-sulfophenyl)−2H-tetrazolium) (MTS) and phenazine methosulfate (PMS)-mediated chemical labelling of benzyl-mercaptan thioalcohol {#s4-7}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Liberated benzyl mercaptan was labelled as follows, 500 μl from each reaction was taken at the appropriate time point and centrifuged at 13 000 r.p.m. for 2 min. To chemically label benzyl-mercaptan, 50 µl of labelling reagent, consisting of 4.09 mM 3-(4,5-dimethylthiazol-2-yl)−5- (3-carboxymethoxyphenyl)−2-(4-sulfophenyl)−2H-tetrazolium (MTS) (Promega) and 0.2 mM phenazine methosulfate (PMS) (Sigma) ([@bib35]), dissolved in dH~2~O, was aliquoted into either a 96 well microplate or 0.5 ml Eppendorf tubes. For reactions using a 96 well microplate, 200 µl reaction supernatant was added to the pre- aliquoted 50 µl MTS/PMS. The plate was sealed with a semi-permeable film lid, incubated at room temperature for 50 min and the A~492nm~ recorded on a Biotek PowerWave XS microplate spectrophotometer. The data was captured by KC junior and exported to Microsoft Excel. For reactions in Eppendorf tubes, 20 µl - 50 µl reaction supernatant was added to 50 µl MTS/PMS. The reaction was incubated at room temperature for 50 min. 20 µl was subsequently removed and diluted in 980 µl dH~2~O in a 1.5 ml disposable plastic cuvette. The A~492nm~ was recorded.

5,5\'-dithiobis-(2-nitrobenzoic acid) (DTNB)-mediated chemical labelling of 3M3SH {#s4-8}
---------------------------------------------------------------------------------

To quantify free 3M3SH, a 75 µl volume from each reaction (isolated as described above) was taken at the appropriate time point and centrifuged at 13, 000 rpm for 2 min. 950 µl labelling solution, consisting of: 800 µl dH~2~O, 100 µl UltraPure Tris (pH 8.0) and 50 µl DTNB ([@bib24]) stock solution (50 mM sodium acetate, 2 mM DTNB, dissolved in dH~2~O) was added to a 1.5 ml disposable cuvette. 50 µl reaction supernatant was added to the cuvette, mixed by pipetting and incubated at room temperature for 5 min. The A~412nm~ was recorded on a Jenway 6305 spectrophotometer. ([@bib81]). Where appropriate, E. coli strains harbouring inducible genes on the pBADcLIC2005 plasmid were pre-induced during overnight growth with 0.0001% L-arabinose. In all experiments cells only (no added substrate) and substrate only (no added cells) were also included.

Protein expression and purification {#s4-9}
-----------------------------------

The gene encoding *S. hominis* SH1446 was cloned into a C-terminal octa histidine GFP fusion vector (pWaldo-GFPe) ([@bib20]) and subsequently transformed into *Escherichia coli* C43(DE3) cells ([@bib54]). Mutations were introduced using site directed mutagenesis followed by DpnI digestion. An overnight starter culture was used to inoculate 4 L of Terrific Broth (TB). Cells were left to grow at 37°C and aerated by shaking at 250 rpm. Overexpression of the fusion protein was induced when the culture reached an OD~600~ of \~0.6, by adding isopropyl-β-D-thiogalactopyranoside (IPTG) to a final concentration of 0.4 mM. Following induction, the temperature was reduced to 25°C. Cells were harvested 16 hr later, and resuspended in phosphate buffered saline (PBS) containing deoxyribonuclease I from bovine pancreas, and stored at −80°C.Unless stated, the following steps were carried out at 4°C. Cells were thawed and disrupted at 32 kpsi (Constant Systems, UK). Cellular debris was removed by centrifugation at 30,000 x *g* for 30 min, and membranes were isolated by ultracentrifugation at 230,000 x *g* for 120 min. Membranes were resuspended in PBS using a dounce homogeniser, flash frozen, and stored at −80°C. Thawed membranes were diluted with 1x PBS (10 mL per gram of membrane), 20 mM imidazole (pH 8.0), 150 mM NaCl, and 1% n-Dodecyl-β-D-maltoside (DDM) and left to solubilise for 60 min, stirring. Non-solubilised membranes were removed by ultracentrifugation at 230,000 *g* for 60 min. Nickel-NTA resin (ThermoFisher Scientific) was added to the sample, using a ratio of 1 mL resin per gram of membrane, and left to bind, stirring, for approximately 90 min. The resin was then packed into a glass econo-column (BioRad, USA) under gravity. The resin was washed with 20 column volumes (CV) of wash buffer (1x PBS, 20 mM imidazole (pH 8.0), 150 mM NaCl and 0.05% DDM). The resin was further washed with 10CV of wash buffer containing 30 mM imidazole. The bound GFP-SH1446 fusion protein was eluted with wash buffer containing 250 mM imidazole. The eluent was combined with an equivalent concentration of hexa histidine tagged TEV protease and dialysed overnight against 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 0.03% DDM. The cleaved protein was filtered using a 0.22 μm filter (Millipore, USA) and passed through a Ni-NTA 5 mL HisTrap column (GE Healthcare) to remove uncleaved GFP-SH1446 protein and TEV protease. The flow through was collected and concentrated to 300 μl using a 50 kDa MWCO concentrator (Vivapsin 20, Sartorius AG) and applied to a size exclusion column (Superdex 200 10/30, GE Healthcare) pre-equilibrated with 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 0.03% DDM. Fractions containing purified SH1446 protein were pooled and concentrated to a final concentration of 15--20 mg.ml^−1^.

For expression and purification of TnaA, overnight cultures were grown in LB at 37°C, 200 rpm. 1 L of LB was inoculated 1:50 with the starter culture and grown to an OD~600nm~ \~0.6--0.8, target protein expression was induced with 0.001% arabinose. Following induction the culture was further incubated at 37°C for \~8 hr. Cells were harvested by centrifugation at 4,500 rpm for 15 min and resuspended in 35 mL resuspension buffer (50 mM Kpi, 20% Glycerol, 200 mM NaCl and 10 mL Imidazole, pH 7.8) and stored at −80°C. All subsequent steps were carried out at 4°C, for protein purification cells were thawed and lysed using sonication with 3 s pulsed and 7 s pause for 3mins. Lysates were clarified by centrifugation 25,000 rpm \~30 min. The clarified supernatant was loaded onto a 5 mL HisTrap column (GE Healthcare) and affinity purified on an AKTA Start (GE Healthcare) using a standard protocol as per manufacturer's instructions.

Protein crystallisation {#s4-10}
-----------------------

Crystals of SH1446 were obtained *in-meso* phase. Briefly, concentrated protein was mixed with 9.9 monoacylglycerol (Monoolein, Sigma-Aldrich) at a protein:lipid ratio of 2:3, in a mechanical syringe mixer at 20°C ([@bib3]). 50 nL of mesophase and 800 nL of precipitant solution was dispensed on to a 96-well glass plate using an *in meso* robot (Gryphon, Art Robbins Instruments). SH1446 S-Cys-Gly-3M3SH complex was crystallised in precipitant solution containing 26--27% (v/v) PEG 200, 220 mM (NH4)~2~HPO~4~, 110 mM sodium citrate (pH 5.0) and 5 mM S-Cys-Gly-3M3SH (Peakdale Molecular) and left overnight at 4°C, prior to crystallisation. Crystals appeared after 2--3 days, and grew to its maximum size after 10 days. Crystallisation wells were accessed using a tungsten-carbide glasscutter, and crystals were directly mounted onto 50--100 μm microloops (MiTeGen) and flash frozen at 100 K.

X-ray diffraction data were collected at ID23-2 at the European Synchrotron Radiation Facility on a Pilatus3 2M detector with an exposure setting of 0.05 s with a 0.2° oscillation range over 360° Diffraction data was indexed and integrated in XDS ([@bib48]) and merged in Aimless ([@bib28]).

Structure solution and refinement {#s4-11}
---------------------------------

The ligand bound complex was solved by molecular replacement in PHASER ([@bib52]) using a modified search model of the bacterial peptide transporter from *Streptococcus thermophilus*, PepT~St~ ([@bib51]), PDB: 4D2B. Iterative rounds of manual model building in COOT ([@bib25]) followed by refinement in autoBUSTER (Bricogne G. 2017) followed by refinement in Phenix ([@bib2]), resulted in a final model, which was validated using the Molprobity server ([@bib13]). Additional difference density was observed in the binding site and matched the stereo chemical properties and size of S-CG3M3SH. Ligand restraints were generated using the Grade Web Server (<http://grade.globalphasing.org>). Figures were prepared using PyMOL (Schrödinger, LLC).

Reconstitution into proteoliposomes and transport assays {#s4-12}
--------------------------------------------------------

Purified SH1446 was detergent exchanged into n-Decyl-β-D-maltopyranoside (DM, Anatrace) using a size exclusion column (Superdex 200 10/30, GE Healthcare) pre-equilibrated with 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 0.3% DM. Lipids (POPE:POPG in a 3:1 ratio) were mixed with the eluted protein at a ratio of 60:1. The protein:lipid mixture was rapidly diluted with 50 mM KPO~4~ (pH 7.0) buffer to below the CMC value of DM. Proteoliposomes were harvested by ultracentrifugation (234,000 *xg*) for 120 min. The pellet was resuspended in 50 mM KPO~4~ and dialysed overnight against 3L of 50 mM KPO~4~ (pH 7.0). Proteoliposomes were recovered and subjected to three rounds of freeze thawing before storage at −80°C.

Proteoliposomes were thawed and harvested by ultracentrifugation at 150,000 *g*. The resulting pellet was carefully resuspended in INSIDE buffer (120 mM KCl, 2 mM MgSO~4~, 5 mM HEPES pH 6.8) and 1 mM pyranine (trisodium 8-hydroxypyrene-1,3,6-trisulfonate). Proteoliposomes underwent eleven freeze-thaw cycles in liquid nitrogen before the sample was extruded through a 0.4 μm polycarbonate membrane and harvested by ultracentrifugation as before. Excess pyranine dye was removed with a Microspin G-25 column (GE Healthcare) pre-equilibrated with INSIDE buffer without pyranine. For the assay, proteoliposomes were diluted into OUTSIDE buffer (120 mM NaCl, 5 mM HEPES (pH 6.8), 2 mM MgSO~4~).

A Cary Eclipse fluorescence spectrophotometer (Agilent Technologies) equipped with a cuvette and magnetic flea was used to carry out the transport assay. Dual fluorescence excitation was set to 460/415 nm with emission at 510 nm. Transport was initiated with 1 μM valinomycin, the resulting data was exported and analysed using Prism (GraphPad Software). Transport data was normalised to one to facilitate comparison with data collected from multiple conditions.

Competition assays {#s4-13}
------------------

Proteoliposomes were harvested as before, the resulting pellet was resuspended in INSIDE buffer, subjected to three freeze-thaw cycles in liquid nitrogen, extruded through a 0.4 μm polycarbonate membrane and harvested by ultracentrifugation once more. For the assay, proteoliposomes were diluted in external buffer (110 mM NaCl, 10 mM NaPO~4~ and 2 mM MgSO~4~) supplemented with 50 μM di-alanine peptide containing trace amounts of tritiated ^3^H-di-alanine (specific activity 30 Ci/mmol) and the competing substrate at increasing concentrations as indicated. Competition assays were performed at 30°C, samples were taken at specified time points and transport was stopped by addition of 2 mL H~2~O. Proteoliposomes were immediately filtered onto a 0.22 μm cellulose filter (Merck Millipore) using a vacuum manifold and subsequently washed twice more with 2 mL H~2~O. The amount of peptide transported into the liposomes was calculated based on the specific activity for each peptide as detailed by the manufacturer and counting efficiency for the radioisotope in Ultima Gold (PerkinElmer) counted in a Wallac scintillation counter (^3^H, 45% counting efficiency). Transport assays were performed a minimum of three times to generate an overall mean and S.E.M.

Data availability {#s4-14}
-----------------

Atomic coordinates for the atomic models have been deposited in the Protein Data Bank under accession numbers 6EXS.
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Decision letter

Boudker

Olga

Reviewing Editor

Weill Cornell Medicine

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Structural basis of malodour precursor transport in the human axilla\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Richard Aldrich as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

The manuscript reports the identification and crystal structure determination of a transporter protein for S-Cys-Gly-3M3SH in *Staphylococcus hominis*. The protein is proposed to import the compound into the bacteria for the processing to 3M3SH, which is released as an underarm odor in humans. The crystallographic work is accompanied by transport and functional assays in whole cell *E. coli* and proteoliposomes. Flexibility of amino acid side chains at the substrate binding site is proposed to be the main factor that allows the transporter to recognize multiple types of peptide-derivatives. To identify the transporter, the authors side-step the genetic intractability of *Staphylococcus* spp. by transferring the relevant biochemical process to *E. coli* and then utilizing both the well characterized functional annotation and the knock-out libraries to dissect the pathways, moving back and forth between *S. hominis* and *E. coli* proteins.

The reviewers agreed that the work is important and should be seen by the broad readership of *eLife*. However, all reviewers agreed that it is not clear from the experiments presented whether the identified transporter is the only or even the main transporter of S-Cys-Gly-3M3SH in *S. hominis*. They felt that to make this conclusion, the authors would need to conduct a knockout experiment. Corresponding genetic tools do exist (e.g. PMID:27531908; PMID: 25104751; PMCID: PMC3709823).

Additional specific comments are:

1\) The affinity for the modified peptide appears to be relatively low in high μM range. Is this affinity compatible with levels of peptide likely encountered under physiological conditions?

2\) How evolutionarily broad is the ability of Staph. species to transport S-Cys-Gly-3M3SH? Are there PepT~Sh~ homologues that are likely unable to transport the peptide because of a mutated binding site? If yes, are these species still able to take up the peptide

3\) Authors may want to be more transparent in the limitations of this study as the major components of this analysis are inferred from non-skin colonizing organisms. For example, the genomic searches were targeted and could not obviate additional proteins playing alternative pathways.

4\) Does the 50% reduction of model substrate 5BLCG in *E. coli*-ΔdtpB cells suggest the existence of one more importer? Such an importer would probably help to explain the discrepancies seen with some mutant activity between proteoliposomes and whole cells. Does such an importer have a homolog in *Staphylococcus hominis*?

5\) The average B-factor of the structure is 57.0, which is fairly low and indicates rigidity for the protein. If the residues at the substrate binding site are flexible as suggested by the authors, do they display higher B-factor values?

6\) From the data presented, is it possible to estimate the turnover rate of the transporter?

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Structural basis of malodour precursor transport in the human axilla\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Richard Aldrich (Senior Editor) and a Reviewing Editor.

There is only one small remaining issue. One of the reviewers has requested that you estimate the turnover rate of the transporter. You have provided the values in your response in nmol/min/mg. I believe that the reviewer wanted to see the numbers in mol/mol/min. It seems to me that this number comes up to approximately 1 mol/mol/min for the wild type transporter (assuming MW ca 50 kDa) unless I made an arithmetic error. This seems a bit slow. Could you please verify the turnover rate and include a comment on it in the manuscript.

10.7554/eLife.34995.028

Author response

> The manuscript reports the identification and crystal structure determination of a transporter protein for S-Cys-Gly-3M3SH in Staphylococcus hominis. The protein is proposed to import the compound into the bacteria for the processing to 3M3SH, which is released as an underarm odor in humans. The crystallographic work is accompanied by transport and functional assays in whole cell E. coli and proteoliposomes. Flexibility of amino acid side chains at the substrate binding site is proposed to be the main factor that allows the transporter to recognize multiple types of peptide-derivatives. To identify the transporter, the authors side-step the genetic intractability of Staphylococcus spp. by transferring the relevant biochemical process to E. coli and then utilizing both the well characterized functional annotation and the knock-out libraries to dissect the pathways, moving back and forth between S. hominis and E. coli proteins.
>
> The reviewers agreed that the work is important and should be seen by the broad readership of eLife. However, all reviewers agreed that it is not clear from the experiments presented whether the identified transporter is the only or even the main transporter of S-Cys-Gly-3M3SH in S. hominis. They felt that to make this conclusion, the authors would need to conduct a knockout experiment. Corresponding genetic tools do exist (e.g. PMID:27531908; PMID: 25104751; PMCID: PMC3709823).

We thank for the reviewers for including these references, which are all genetic tools to manipulate *S. aureus*. This important pathogen has been studied for many decades and its genetic tractability has been facilitated by the generation of restriction/modification (RM) deficient strains such as RN4220 that will accept DNA from a wide range of sources. Even so, such DNA often requires passage through special *E. coli* strains modified to give the correct modification patterns that prevents their immediate degradation when transformed into *S. aureus*. Coagulase negative species of *Staphylococci* include the dominant skin bacterium *S. epidermidis*, for which a few of the tools developed for *S. aureus* can work, however *S. hominis* is poorly studied coagulase negative species of *Staphylococcus* for which no genetic tools have previously been tested or developed. We have tried extensively to genetically manipulate *S. hominis* for this study; however, due the presence of multiple RM systems (it contains at least 4 from our in silicoanalysis) the strain is extremely refractory to the introduction of any foreign DNA, an essential initial step for undertaking any genetic engineering. There is not a single example in the literature of a gene knock-out in this species and to develop the tools to do this is a major project in itself.

However, we fully appreciated the reviewers concern that the evidence that the identified transporter "is the only or even the main transporter of *S*-Cys-Gly-3M3SH in *S. hominis*" and we have undertaken significant additional experimentation to demonstrate this.

Our strategy is to examine the inhibitory profile of peptides to whole cell systems that are able to produce 3M3SH. In the initial submission, we did not clearly explain that *S. hominis* and other *Staphylcocci* only contain a single POT transporter (Figure 2---figure supplement 4). In addition to one POT they contain between 1-4 ABC transporters of the Opp family. An important experimental study on the relative function of these peptides transporters in *S. aureus* demonstrated that only one of the ABC transporters (Opp-3) was important for use of oligopeptides (from 3 to 8 amino acids), while the POT transporter was essential for growth on all dipeptides and some tripeptides. (Hiron et al., 2007). Therefore, we reasoned that if di- and tripeptides could inhibit the production of 3M3SH whereas free amino acids and longer peptides could not then this would be strong biochemical support that they were entering via the POT transporter that we characterised in this study.

Using whole-cell systems we measure the ability of different peptides to inhibit production of 3M3SH. In our *E. coli* system, where the expression of the *S. hominis* POT protein SH1446 is essential to observe 3M3SH production, the process is inhibited by both di- and tri-peptides but not L-Ala or tetra-Ala (presented as new data in Figure 2---figure supplement 4). The same four molecules were tested at the same concentrations against purified TnaA, the cytoplasmic enzyme that cleaves the peptide-linked thioalcohol to 3M3SH and they have no effect (Figure 2---figure supplement 5), demonstrating that the observed inhibition is at the level of transport.

We then repeated these experiments in *S. hominis* directly and observed a similar pattern. This is especially significant for the di-peptide, which specifically inhibits the POT transporter and not the ABC transporter, while we do also see inhibition with the tripeptide. The inhibition observed at the highest concentration of tetra-Ala is an artefact of the low pH required to keep the chemical in solution, which is impacting negatively on the *S. hominis* cells.

From these data we are now really confident that the SH1446 protein is the major route of CysGly-3M3SH uptake in *S. hominis*.

> Additional specific comments are:
>
> 1\) The affinity for the modified peptide appears to be relatively low in high μM range. Is this affinity compatible with levels of peptide likely encountered under physiological conditions?

The physiological concentrations of S-Cys-Gly-3M3SH in the axilla are not known, so it is difficult to comment on this. We note that the enzyme that produces S-Cys-Gly-3M3SH from glutathionyl3M3SH, the human GGT1 enzyme, has been partially biochemically characterised (Baumann et al., 2014) and 1 mM substrate was used in their assays perhaps suggesting that the concentration of the precursors for secretion in the axilla cells is in this region, although a precise *K*~M~ for this enzyme was not determined. We would not expect the affinity of the transporter to be particularly high given that SH1446 is likely the main route by which the organism acquires dipeptides and some tripeptides, but speculate that it is high enough to be able to result in the small flux required to move S-Cys-Gly-3M3SH into the cell for its biotransformation.

> 2\) How evolutionarily broad is the ability of Staph. species to transport S-Cys-Gly-3M3SH? Are there PepT~Sh~ homologues that are likely unable to transport the peptide because of a mutated binding site? If yes, are these species still able to take up the peptide?

The single POT transporter present in *S. hominis* is present in most *Staphylococi* and therefore we speculate that most other *Staphylococci* can transporter the precursor. In related work we have discovered a particular CS-lyase enzyme specific to the malodour producing species of *Staphylococci* that we speculate influences whether bacteria make 3M3SH or not. In our phylogenetic analysis of the POT transporters, we show that most *Staphylococci* species contain an orthologous *PepT~Sh~* system, with some CoNS stains possessing two proteins. All these proteins contain the conserved motif ExxERF/YY, essential for protonation and peptide binding (1). As outlined in the paper the conserved features of *PepT~Sh~* classify it as an archetypal POT family transporter, the unique hydrophobic pocket that specifically accommodates our physiologically relevant substrate allows for this di- tri peptide (DtpT) permease to transport modified dipeptides. Without detailed structural information, we are unable to compare this *PepT~Sh~* with closely related organisms.

> 3\) Authors may want to be more transparent in the limitations of this study as the major components of this analysis are inferred from non-skin colonizing organisms. For example, the genomic searches were targeted and could not obviate additional proteins playing alternative pathways.

We recognise one of the major limitations of this study is the inability to genetically manipulate *S. hominis* to create functional knockouts. We have now provided more evidence in our *E. coli* model for the role of *PepT~Sh~*in S-Cys-Gly-3M3SH transport in terms of selectively inhibiting *PepT~Sh~*. The new data further supports the inhibition seen for both wild-type *S. hominis* and *E. coli* overexpressing *PepT~Sh~*. We are confident in our *in silico* analysis that *S. hominis* contains a single DtpT POT system, and that this is the peptide transport system required for the transport *S-*CysGly-3M3SH.

> 4\) Does the 50% reduction of model substrate 5BLCG in E. coli-ΔdtpB cells suggest the existence of one more importer? Such an importer would probably help to explain the discrepancies seen with some mutant activity between proteoliposomes and whole cells. Does such an importer have a homolog in Staphylococcus hominis?

The 50% reduction, and not total loss of activity in the *E. coli-ΔdtpB* strain is not surprising given that *E. coli* contains 4 POT transporters, named DtpA-D, each with distinct and overlapping substrate specificities that are involved in di- and tri-peptide uptake (Figure 2B) (2) and so the residual activity is almost certainly through the activity of one of these systems. We have a separate publication in preparation on the physiological functions of these 4 transporters and can report that a strain with all 4 deleted has completely lost the ability to produce 3M3SH (Bawdon et al., in preparation). This data further supports our hypothesis that the POT transporters are the sole route of Cys-Gly-3M3SH entry into bacteria, remembering that *S. hominis* has only a single POT system (SH1446 in *S. hominis*) and there are not multiple homologs like in *E. coli*.

> 5\) The average B-factor of the structure is 57.0, which is fairly low and indicates rigidity for the protein. If the residues at the substrate binding site are flexible as suggested by the authors, do they display higher B-factor values?

The flexibility we refer to in the manuscript concerned the ability of the binding site to recognise ligands in different binding modes and conformations, as demonstrated in the homologous transporter PepT~St~ (5). We did not intend to infer that the side chains are structurally flexible in the structure -- or indeed, are any more flexible that in other related POT family transporters. Indeed, S-CG-3M3SH is well coordinated in the binding site and has similar B-factors to the surrounding side chains (80 vs 54 Å^2^). We have now revised the wording in the manuscript.

"Taken together the current data lend further support to our model of an adaptablebinding site within the POT family that can accommodate chemically diverse peptides and their derivatives through the use of both side chain and water mediated interactions with conserved residues and different specificity pockets to accommodate the different chemical side chains.**"**

> 6\) From the data presented, is it possible to estimate the turnover rate of the transporter?

We have calculated the turnover number for the transporter as follows:

Wild-Type 189 ± 37 nmol/min/mg

Y41A: 7.2 ± 0.58

Y41F 6.5 ± 0.40

N347A 42.9 ± 0.30

Y411W 34.0 ± 3.45

![](elife-34995-resp-fig1){#respfig1}

All the variants we infer mechanistic information from are functional, although clearly some changes have more negative effects than others. We try, wherever practically possible to take into account changes in *K*~M~ values when undertaking assays on functionally affected variants, such as Y41A/F in the study.
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\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:
>
> There is only one small remaining issue. One of the reviewers has requested that you estimate the turnover rate of the transporter. You have provided the values in your response in nmol/min/mg. I believe that the reviewer wanted to see the numbers in mol/mol/min. It seems to me that this number comes up to approximately 1 mol/mol/min for the wild type transporter (assuming MW ca 50 kDa) unless I made an arithmetic error. This seems a bit slow. Could you please verify the turnover rate and include a comment on it in the manuscript.

Thank you for giving us the opportunity to submit our revised manuscript titled "Structural basis of malodour precursor transport in the human axilla'. Our calculations put the turnover number at 10. The WT transport rate was determined as \~189 nmol/min/mg using 50uM di-alanine as substrate. The MW of PepT~Sh~ is 55361Da, giving 18.06 nmol in 1mg. So, 189/18 = 10.5. I have included this the paper after we describe the IC~50~ data:

"To understand the recognition of S-Cys-Gly-3M3SH compared to natural peptides, we determined IC50 values using competition with 3H-di-alanine. The IC~50~ value for tri-alanine, dialanine and Cys-Gly were 23.7 ± 3.4, 72.2 ± 9.7 and 115 ± 22.2 μM, respectively (Figure 3B), indicating that PepT~Sh~ is able to recognise tri-Ala more favourably than di-Ala. However, for S-Cys- Gly-3M3SH the IC~50~ value was 362 ± 21.8 μM, three-fold higher than the Cys-Gly peptide. The turnover number of PepT~Sh~ for di-peptide transport was calculated as \~10 per minute. Our data therefore show that while PepT~Sh~ can transport the modified peptide, the addition of the thioalcohol group on the cysteine side chain has substantially impaired the recognition and transport versus natural peptides."

10 turnovers per minute is at the lower end of activity for the bacterial peptide transporters we have worked with. PepTSo in contrast is \~ 10x faster at 100 turnovers/minute for example. I am happy to comment on this if the referee thinks this may have an impact on the interpretation of our competition results. I must admit, we didn't consider 10 to be abnormally slow when interpreting the assay results.
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